AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00245570
Drug: Comparator: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 dose montelukast 10 mg tablet given orally in one of three treatment periods
Trial: NCT00245570
Drug: Comparator: Salmeterol
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
Trial: NCT00008333
Drug: vinorelbine tartrate
RxNorm normalized name: Vinorelbine Tartrate
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04285684
Drug: ketamine in lactation
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 dose IM by weight and assessing concentrations of ketamine in expressed milk at intervals
Trial: NCT01975649
Drug: Tribulus Terrestris
RxNorm normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will use 750 mg/day during 120 days
Trial: NCT00585585
Drug: betahistine dihydrochloride
RxNorm normalized name: Betahistine Dihydrochloride
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 50-300 mg, daily
Trial: NCT03794323
Drug: BI 764122
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT00937911
Drug: YM150
RxNorm normalized name: Yohimbine
DrugBank: Yohimbine (DB01392)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT03055221
Drug: Intravenous Treprostinil
RxNorm normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
Trial: NCT04461535
Drug: Adrenocorticotropic hormone
RxNorm normalized name: Adrenocorticotropic hormone
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients divided into Intervention group need to undergo stimulation with a continuous cosyntropin infusion (50 μg/h started 30 minutes before sampling during AVS). Right and left adrenal venous blood and corresponding peripheral venous blood should be sampled sequentially.
Trial: NCT02011464
Drug: Exparel
RxNorm normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exparel is infiltrated into posterior compartment for pain control
Trial: NCT00153920
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03191201
Drug: Ferric Carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
Trial: NCT03191201
Drug: 0.9% sodium chloride solution
RxNorm normalized name: Precedex 80mcg/20mL in 0.9% Sodium Chloride Solution for Injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mL of a commercially available sterile 0.9% sodium chloride solution.
Trial: NCT05219656
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue therapy in acute severe ulcerative colitis
Trial: NCT01014520
Drug: Gabapentin , Amitriptyline
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule, 300 mg, oral, single dose 2 hours before surgery~Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery
Trial: NCT00045955
Drug: Fexofenadine, Comparator = Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02021604
Drug: Fluorodopa F 18
RxNorm normalized name: FLUORODOPA F-18
DrugBank: Fluorodopa (18F) (DB13848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
Trial: NCT03908008
Drug: Botox (Botulinum toxin type A)
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Trial: NCT03908008
Drug: MT10107 (Botulinum toxin type A)
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.
Trial: NCT00604539
Drug: Chondroitin sulphate (Condrosan)
DrugBank: Chondroitin sulfate (DB09301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg (two capsules of 400 mg each) taken once a day for one year
Trial: NCT03967964
Drug: Dehydroepiandrosterone Oral Capsule
RxNorm normalized name: DEHYDROEPIANDROSTERONE
DrugBank: Prasterone (DB01708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule containing 25 mg DHEA
Trial: NCT03418974
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive pitavastatin treatment for 3 or 12 weeks.
Trial: NCT03418974
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsule/Tablet, oral, follow the doctor's advice Participants will receive atorvastatin treatment for 3 or 12 weeks.
Trial: NCT00710554
Drug: Sativex
RxNorm normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Trial: NCT00841074
Drug: chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine mouthwash spray, \~1.3 ml, twice a day.
Trial: NCT01164956
Drug: methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00967798
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
Trial: NCT01409564
Drug: Cilostazol
RxNorm normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
Trial: NCT01036035
Drug: Tolterodine
RxNorm normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drug
Trial: NCT01036035
Drug: Pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparison of different dosages of drug
Trial: NCT04615923
Drug: Pridopidine
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration: Oral~Dose: 45mg twice daily
Trial: NCT00045500
Drug: 7-hydroxystaurosporine
RxNorm normalized name: 7-Hydroxystaurosporine
DrugBank: 7-Hydroxystaurosporine (DB01933)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00045500
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03527095
Drug: FDL169
RxNorm normalized name: FDL169
DrugBank: FDL169 (DB16878)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFTR corrector
Trial: NCT02282020
Drug: OLAPARIB
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
Trial: NCT01685931
Drug: Paliperidone Palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
Trial: NCT00785395
Drug: Oxytocin infusion
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Up-down dosing determination
Trial: NCT02244489
Drug: Momelotinib (MMB)
RxNorm normalized name: momelotinib
DrugBank: Momelotinib (DB11763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Momelotinib (MMB) tablet(s) administered orally once or twice daily
Trial: NCT02244489
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.
Trial: NCT01610947
Drug: Adalimumab, Etanercept, Golimumab or infliximab
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuation of usual treatment with fixed intervals according to standard recommendations
Trial: NCT01610947
Drug: Adalimumab, Etanercept, Golimumab or infliximab
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
Trial: NCT02097407
Drug: Group C : Saline + propofol group
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment
Trial: NCT02097407
Drug: Group D : Dexmedetomidine + propofol group
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.~After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment.
Trial: NCT00551733
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00551733
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT00551733
Drug: paclitaxel poliglumex
RxNorm normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00745147
Drug: Duphalac
RxNorm normalized name: Duphalac
DrugBank: Lactulose (DB00581)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
Trial: NCT03518073
Drug: Zagotenemab
RxNorm normalized name: Zagotenemab
DrugBank: Zagotenemab (DB16674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT00475176
Drug: Peginterferon alfa-2a
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00475176
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00301574
Drug: galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02069990
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03804879
Drug: Nidufexor
RxNorm normalized name: Nidufexor
DrugBank: Nidufexor (DB16255)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg (two 25 mg) LMB763 capsules for oral administration
Trial: NCT03823352
Drug: Antroquinonol
RxNorm normalized name: Antroquinonol
DrugBank: Antroquinonol (DB12326)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
Trial: NCT01428973
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
Trial: NCT01428973
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets. 6 mg loading dose on day -3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
Trial: NCT00358228
Drug: Rimonabant
RxNorm normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT00911495
Drug: GMI-1070
RxNorm normalized name: GMI-1070
DrugBank: Rivipansel (DB12778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GMI-1070 given as two doses over the course of one day
Trial: NCT03206645
Drug: Unesbulin
RxNorm normalized name: Unesbulin
DrugBank: Unesbulin (DB18080)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unesbulin will be given in combination with carboplatin and paclitaxel for up to 7 cycles depending on which cohort the patient is in.
Trial: NCT01484873
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
Trial: NCT01305850
Drug: Aliskiren
RxNorm normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Trial: NCT01305850
Drug: Aliskiren plus Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Trial: NCT01305850
Drug: Enalapril plus Losartan
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Trial: NCT00100815
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
Trial: NCT04237090
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug identification number : 02369567
Trial: NCT04237090
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug identification number : 02231603
Trial: NCT04237090
Drug: Sodium chloride 0.9%
RxNorm normalized name: SODIUM CHLORIDE 0.9% INJ
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug identification number : 00037796
Trial: NCT01953341
Drug: AMG 333
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration available in varying dose strength.
Trial: NCT01830660
Drug: Hetrombopag Olamine Tablets
RxNorm normalized name: Eltrombopag Olamine
DrugBank: Hetrombopag (DB16184)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04357392
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone 10mg, TID \* 2 weeks, decreasing 5mg per week, continuous treatment for 8 weeks
Trial: NCT01635972
Drug: Isavuconazole
RxNorm normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01635972
Drug: bupropion hydrochloride
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02278263
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously or topically
Trial: NCT02278263
Drug: Normal saline (0.9% NaCl)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered in all 3 groups
Trial: NCT01216280
Drug: 10 mg Natura-alpha capsule and 10 mg placebo capsule
RxNorm normalized name: alpha tocopherol 10 MG
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
Trial: NCT01216280
Drug: 2 x 10 mg Natura-alpha capsules
RxNorm normalized name: alpha tocopherol 10 MG
DrugBank: Tocopherol (DB11251)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
Trial: NCT00949078
Drug: omalizumab
RxNorm normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
Trial: NCT00965094
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
Trial: NCT00965094
Drug: Tacrolimus (FK506)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules 0.5 mg, 1 mg. Dosing according to blood level.
Trial: NCT00965094
Drug: Basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One vial containing 20 mg lyophilisate. 2 x 20 mg \[day 0 (2 hrs prior to Tx) and day 4 post Tx\] to be applied as 10 sec. bolus injection, i.v.
Trial: NCT00532857
Drug: Paclitaxel/Gemcitabine/Trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
Trial: NCT03996460
Drug: 192 mg powder of K0706
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifteen (15) patients in group 2 will receive the sachet of 192 mg powder of K0706 ( equivalent to 96 mg capsule of K0706) orally for 12 weeks (90 days) without food.
Trial: NCT03996460
Drug: 384 mg powder of K0706
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifteen (15) patients in group 3 will receive the 384 mg powder of K0706 (equivalent to 192 capsule of K0706) orally daily for 12 weeks (90 days) without food.
Trial: NCT02491450
Drug: Sovaldi
RxNorm normalized name: Sovaldi
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet contains 400 mg sofosbuvir